Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07545980Recruiting
CelluJuve for moderate to severe forehead wrinkles
This study tests CelluJuve®, an injectable filler, to smooth moderate to severe forehead wrinkles (called nasolabial folds). The goal is to see if it safely improves wrinkle appearance over time.
Coral Gables, FloridaAges 22 years+ - NCT06994650RecruitingPhase 3
Study of HRS9531 for sleep apnea and obesity
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
Beijing, Beijing MunicipalityAges 18–75 - NCT06988618Recruiting
Real-world use of nemolizumab for adults with prurigo nodularis
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
Birmingham, AlabamaAges 18 years+ - NCT07038720RecruitingPhase 1
Testing an experimental oral tablet for moderate to severe psoriasis
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hangzhou, ZhejiangAges 18–55 - NCT04876781Recruiting
Track safety of Xeljanz XR in Korea
This study collects real-world safety information about Xeljanz XR after it has been approved. It includes people with certain immune-related joint diseases and checks for side effects in everyday use.
SeoulAges 18 years+ - NCT06531798RecruitingPhase 4
Safety study of Breztri aerosphere in Indian COPD patients
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
Dalgate, DrugjanAges 18 years+ - NCT07643220RecruitingPhase 1
Comparing Two Versions of a Hair-Loss Medication
This study tests whether two versions of the same medication (AJU-G721 and G721R)—used to treat hair loss and urinary symptoms—work the same way in the body. Researchers will measure how much medication gets absorbed and how long it stays in your system.
SeoulAges 19–54 - NCT07337434RecruitingEarly Phase 1
Comparing two pills for moderate to severe psoriasis
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Peshawar, Khyber PukhtunkhwaAges 18–60 - NCT07748091Recruiting
Brain wave and inflammation markers in shock therapy for depression
This study looks at brain wave patterns and markers of inflammation in people with depression that hasn't improved with other treatments and who are receiving electroconvulsive therapy (ECT, also known as shock therapy). The goal is to understand how these markers might relate to how well ECT works.
Istanbul, BakırköyAges 18–60 - NCT07746583Recruiting
Switching from ustekinumab to guselkumab for psoriasis
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
BudapestAges 18 years+ - NCT07725939RecruitingPhase 2
Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Boerne, TexasAges 40–80 - NCT07740694Recruiting
ECT study for older adults with depression
This study looks at how ECT affects brain activity and inflammation in older adults with depression. It may help researchers understand why ECT works and improve treatment.
Istanbul, BakırköyAges 55 years+ - NCT07442045Recruiting
Comparing combined vs single drug for ulcerative colitis
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Foshan, GuangdongAges 18 years+ - NCT07192016RecruitingPhase 4
MRI study of triple inhaler for COPD with breathlessness
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
London, OntarioAges 50–85 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+ - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT07734441RecruitingEarly Phase 1
Itraconazole vs Ketoconazole for Scalp Seborrheic Dermatitis
This study compares two treatments—itraconazole pills and ketoconazole shampoo—for moderate to severe dandruff on the scalp. It aims to find which works better for teens aged 14–17.
Chak Four Hundred Fifty-four, Punjab ProvinceAges 18–65 - NCT07301255RecruitingPhase 2
ENV-294 for moderate-to-severe asthma in adults
This trial tests an experimental drug called ENV-294 in adults with moderate-to-severe asthma. You may join if you are already using two kinds of inhalers regularly and have had at least one asthma flare-up in the past year that needed steroids or a hospital visit.
Birmingham, AlabamaAges 18–75
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,480 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.